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Abstract  1 
Background:  Provitamin A carotenoids are a significant source of dietary vitamin A for many 2 
populations.  Thus, accurate and simple methods for estimating carotenoid bioefficacy are 3 
needed to evaluate the vitamin A value of test solutions and plant sources.  β-Carotene 4 
bioefficacy is often estimated from the ratio of areas under plasma isotope response curves after 5 
subjects ingest labeled β-carotene and a labeled retinyl acetate reference dose (isotope 6 
reference method; IRM) but, to our knowledge, the method has not yet been evaluated for 7 
accuracy. 8 
Objective:  Objectives were to (1) develop and test a physiologically-based compartmental 9 
model that includes both absorptive and post-absorptive β-carotene bioconversion and (2) use 10 
the model to evaluate the accuracy of the IRM and a simple plasma retinol isotope ratio (RIR; 11 
labeled β-carotene-derived retinol / labeled reference dose-derived retinol in one plasma sample) 12 
for estimating relative bioefficacy.  13 
Methods:  We used model-based compartmental analysis (Simulation, Analysis and Modeling 14 
software) to develop and apply a model that provided known values for β-carotene bioefficacy.  15 
Theoretical data for ten subjects were generated by the model and used to determine bioefficacy 16 
by RIR and IRM; predictions were compared to known values.  We also applied RIR and IRM to 17 
previously-published data.  18 
Results:  Plasma RIR accurately predicted β-carotene relative bioefficacy at 14 d or later.  IRM 19 
also accurately predicted bioefficacy by 14 d, except that, when there was substantial post-20 
absorptive bioconversion, IRM underestimated bioefficacy.  Based on our model, 1 d predictions 21 
of relative bioefficacy include absorptive plus a portion of early post-absorptive conversion. 22 
Conclusion:  The plasma RIR is a simple tracer method that accurately predicts β-carotene 23 
relative bioefficacy based on analysis of one blood sample obtained at 14 d or longer after co-24 
ingestion of labeled β-carotene and retinyl acetate.  The method also provides information about 25 
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the contributions of absorptive and post-absorptive conversion to total bioefficacy if an additional 26 
sample is taken at 1 d.  27 
Key words:  β-carotene; bioconversion; bioefficacy; carotenoids; humans; isotope reference 28 
method; model-based compartmental analysis; retinoids; retinol isotope ratio; WinSAAM  29 
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Introduction 30 
Provitamin A carotenoids, especially β-carotene, are an important dietary source of vitamin A, 31 
especially in low-income countries where vitamin A deficiency remains a public health problem 32 
(1).  Available data, based mainly on results for β-carotene, indicate that the bioavailability and 33 
bioconversion of provitamin A carotenoids to vitamin A [i.e., bioefficacy (2)] are affected by many 34 
factors, including food matrix, preparation methods, genetics, age, etc. (3).  Although several 35 
methods have been proposed and used to measure β-carotene bioefficacy (4, 5), none are ideal 36 
for use in the field; in addition, none have been verified by comparison to known reference 37 
values.  Researchers need a simple, accurate, and feasible method to assess bioefficacy 38 
because of β-carotene’s contribution to whole-body vitamin A stores and plasma retinol 39 
homeostasis. 40 
Recently (6), we used model-based compartmental analysis to study plasma retinol 41 
kinetics and to estimate relative bioefficacy of β-carotene in healthy adults who had consumed 42 
stable isotope-labeled β-carotene and a reference dose of labeled retinyl acetate.  As we 43 
analyzed the data, the disposition of the two plasma isotope response curves led us to 44 
hypothesize that β-carotene bioefficacy relative to the reference dose could be estimated from 45 
the ratio of the two isotopes in a single blood sample, analogous to the plasma dual isotope ratio 46 
method for determining cholesterol absorption that was developed and tested by Zilversmit (7) 47 
and adapted by Green and Green for vitamin A absorption (8).  In fact, mean β-carotene relative 48 
bioefficacy calculated from the plasma retinol isotope ratio (RIR6) on d 2 was 12.5%, close to the 49 
values determined by modeling (13.5%) or by graphical methods based on areas under the 50 
plasma retinol tracer response curves (“area under the curve;” AUCp) (13.1%) (6).  We found that 51 
similar plasma retinol ratio methods for estimating bioefficacy had been previously postulated by 52 
Hickenbottom at al. (9) and Van Loo-Bouwman et al. (10), but the approach has apparently not 53 
received additional attention.   54 
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Here, we further investigate the plasma retinol isotope ratio for measuring β-carotene 55 
relative bioefficacy.  We used model-based compartmental analysis (11) and the Simulation, 56 
Analysis and Modeling software (12) to verify the accuracy of the technique by first developing 57 
and then applying a compartmental model that would predict assigned values for β-carotene 58 
bioefficacy over a physiologically-reasonable range (5).  We confirmed that our physiologically-59 
based model predicted these assigned bioefficacies and then used the model to generate 60 
corresponding plasma isotope response data.  Finally, we used the simulated plasma data to 61 
calculate relative bioefficacy by the plasma RIR and the isotope reference method [IRM (13)] and 62 
compared predictions to the known values.  The IRM, in which the ratio of areas under the 63 
plasma isotope response curves after subjects ingest doses of labeled β-carotene and retinyl 64 
acetate, has been previously used to estimate β-carotene relative bioefficacy by several 65 
investigators, as reviewed by Tang (13).  In addition to providing a way to evaluate the accuracy 66 
of the two methods, our model development and interpretation also provided insights into the 67 
complex processes and time course of the bioconversion of β-carotene to retinol, including its 68 
absorptive (intestinal) and post-absorptive (extra-intestinal) components.  We show that the 69 
plasma retinol isotope ratio provides a simple, accurate, and easily-used method for estimating β-70 
carotene relative bioefficacy.  71 
 72 
Methods 73 
Subjects.  We selected ten subjects (see next paragraph) from previously-published studies in 74 
which participants received oral doses of stable isotope-labeled β-carotene and a labeled retinyl 75 
acetate reference dose.  In one case (14), the reference dose was ingested 3 d after the dose of 76 
labeled β-carotene; plasma retinol tracer responses were measured for 56 (β-carotene-derived 77 
retinol) and 53 d (for retinyl acetate-derived retinol); β-carotene relative bioefficacy was estimated 78 
using the IRM.  Subsequently, data for labeled plasma retinol derived from the retinyl acetate 79 
dose were modeled by Cifelli et al. (15) using WinSAAM v. 3.3.0 (12) to determine kinetic 80 
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parameters for retinol metabolism.  In the second case (16), subjects ingested simultaneous oral 81 
doses of labeled β-carotene and retinyl acetate; plasma tracer responses were measured for 14 82 
d; Green et al. (6) retrospectively modeled plasma retinol data for the two labels and used 83 
WinSAAM to estimate β-carotene relative bioefficacy for subjects whose results indicated little to 84 
no post-absorptive β-carotene bioconversion.   85 
For the current work, our sample (n=10) includes individuals with a wide range of total 86 
body vitamin A stores (66 – 2500 µmol; Supplemental Table 1) and known vitamin A kinetics.  87 
We selected six subjects from the study of Cifelli et al. (15) [including the ones from Tang et al. 88 
(14) reported to have the lowest, average, and highest conversion of β-carotene] plus four 89 
subjects from Green et al. (6).  Simulated data based on both published (6, 15) and assigned 90 
kinetic parameters for these individuals were used to advance understanding of β-carotene 91 
bioconversion and to evaluate the accuracy of the IRM and the newly-described plasma RIR for 92 
estimating β-carotene relative bioefficacy.  We deemed ten to be an adequate number of subjects 93 
because it allowed for inclusion of a wide range of bioefficacies with differing contributions from 94 
absorptive and early/late post-absorptive bioconversion.  Since we needed to have known values 95 
for bioefficacy in order to test the accuracy of predictions by the two methods, we assigned 96 
known, physiologically-reasonable values for total bioefficacy, including the absorptive and post-97 
absorptive components, to each subject (see later).  98 
 99 
Compartmental models.  We used the six-compartment model presented by Green et al. (6) 100 
(Figure 1A) to describe the metabolism of retinyl acetate-derived retinol.  In Figure 1A, 101 
components 1 to 4 represent the processing of dietary preformed vitamin A until it reaches the 102 
liver and is secreted into plasma compartment 5 as retinol bound to retinol-binding protein; retinol 103 
in the plasma pool exchanges with vitamin A in the storage pool (compartment 6), which is also 104 
the site of irreversible loss from the system.   105 
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 Next, we developed a partially-parallel model (Figure 1B) that describes trafficking of 106 
labeled retinol derived from the conversion of absorbed β-carotene during both absorptive 107 
(intestinal) and early plus late post-absorptive (extra-intestinal) phases.  A “partially-parallel 108 
model” means that we used the same values for kinetic parameters in the model for β-carotene-109 
derived retinol as we used in the model for retinyl acetate-derived retinol when we were 110 
describing biochemical and physiological processes that one logically assumes to be identical for 111 
the two labels.  It should be emphasized that this work focuses on retinol derived from the labeled 112 
β-carotene dose (i.e., on β-carotene that is converted to retinol and secreted into plasma after 113 
conversion).  For the absorptive / intestinal pathway (Figure 1B, unshaded components), the 114 
model was parallel to the one in Figure 1A; that model had been developed (6) for subjects 115 
whose data indicated little to no post-absorptive conversion of absorbed β-carotene to retinol.  116 
For the post-absorptive / extra-intestinal pathway (Figure 1B, shaded components), we used 117 
aspects of the model presented by Novotny et al. (17) as well as other information in the literature 118 
(18-20).  In Figure 1B, components 11 to 13 represent the processes of digestion and absorption 119 
of β-carotene; compartment 11 is the site of splitting of the β-carotene dose into the fraction 120 
eventually converted to retinol (that which is transferred to compartment 12) versus that which 121 
does not contribute to bioefficacy.  Bioefficacy was partitioned into absorptive and post-absorptive 122 
components at delay component 13 as follows.  For the intestinal bioconversion pathway, 123 
absorbed β-carotene is converted to retinol and packaged in chylomicrons, and the retinol 124 
(primarily retinyl esters) is transferred to compartment 14.  For the post-absorptive pathway, 125 
chylomicron β-carotene is transferred from component 13 to compartment 21, which represents 126 
tissue uptake (both extrahepatic and hepatic) of β-carotene from chylomicrons or chylomicron 127 
remnants.  This β-carotene can be converted to retinol in tissues (compartment 24), representing 128 
early post-absorptive conversion (solid-line arrow), or it may be delayed by passing from 129 
compartment 21 through components 22 and 23 (possibly plasma lipoproteins or adipocyte lipid 130 
droplets; see Discussion) before conversion to retinol and passage into compartment 24, 131 
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representing late post-absorptive conversion (dashed-line arrows).  Similar to the models 132 
developed by Green et al. (21) and Novotny et al. (17), retinol in compartment 24 is then either 133 
secreted directly into plasma compartment 15 bound to retinol-binding protein or esterified for 134 
storage in compartment 16.  135 
 136 
Assignment of known values for β-carotene bioefficacy, including both absorptive and post-137 
absorptive components.  In order to obtain known reference values for bioefficacy against which 138 
we could evaluate the RIR and IRM, we chose ten values for β-carotene relative bioefficacy 139 
ranging from 10 to 50%, reflecting the variability reported in the literature (5); then we assigned a 140 
value to each subject.  Assignments were made based on individual total body vitamin A stores 141 
(Supplemental Table 1); the results of Green et al. (6), which indicated that the subjects in that 142 
study had little post-absorptive conversion; and the results of Tang et al. (14), from which we 143 
selected the three subjects that were reported to be the lowest, average, and highest converters 144 
of β-carotene.  Each level of relative bioefficacy was then partitioned into hypothetical but 145 
physiologically-reasonable values for absorptive (7 – 40%) and post-absorptive (3 – 20%) 146 
components.  For example, for subject 1, we assigned a total relative bioefficacy of 10% and 147 
attributed 7% bioefficacy to intestinal bioconversion and 3% to extra-intestinal processes.  148 
Additionally, each value for post-absorptive conversion was partitioned into early and late 149 
components (e.g., 2.4% early and 0.6% late for subject 1).  As described in Supplemental 150 
Methods 1, we simulated the model for each individual to verify that it accurately predicted the 151 
assigned values for the various components of bioefficacy.  152 
 153 
Use of compartmental analysis to generate plasma isotope data for retinyl acetate- and β-154 
carotene-derived retinol.  To generate plasma retinol tracer response data [fraction of dose in 155 
plasma (FDp) versus time] for the retinyl acetate reference dose, we used the kinetic parameters 156 
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reported for the ten subjects (Supplemental Table 1), including an absorption efficiency of 75%, 157 
as inputs in the compartmental model presented by Green et al. (6) (Figure 1A).  Time points 158 
(n=21; 0, 3, 6, 9, and 11 h, then daily for 9 d, and weekly from 14 to 56 d) for the simulation were 159 
based on the study of Tang et al. (14), in which extensive blood sampling had been done to 160 
provide the detailed plasma tracer kinetic curves needed for model-based compartmental 161 
analysis.   162 
Next, to generate corresponding data for β-carotene-derived retinol, we fixed parameters 163 
in the model shown in Figure 1B at the values presented in Supplemental Table 1.  These 164 
included model parameters described in Supplemental Methods 2 that generated the assigned 165 
values for total, absorptive, and post-absorptive (early and late) bioefficacy.  Then, data for FDp 166 
versus time (3 h to 56 d) were simulated to generate plasma tracer response profiles for retinol 167 
derived from the β-carotene dose for each of the ten subjects at the various levels of bioefficacy.  168 
For each subject, simulations resulted in plasma data for labeled retinol derived from three 169 
sources: the retinyl acetate reference dose, absorptive (intestinal) conversion of β-carotene to 170 
retinol, and post-absorptive (extra-intestinal, early and late) conversion of β-carotene to retinol.  171 
Datasets for FDp versus time were used to calculate β-carotene relative bioefficacies based on 172 
plasma isotope ratios and areas under the curves as described in the next sections. 173 
 174 
Calculation of β-carotene relative bioefficacy from the plasma retinol isotope ratio.  Relative 175 
bioefficacy was calculated for the datasets described above based on retinol isotope ratios in 176 
plasma at specific times using Equation 1: 177 
 178 
RIR relative bioefficacy (%) = (FDp for labeled β-carotene-derived retinol /  179 
              FDp for labeled retinyl acetate-derived retinol) × 100   (1) 180 
 181 
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The plasma RIR was calculated using FDp data in molar retinol activity equivalents (1 µmol β-182 
carotene = 2 µmol retinol) at times from 1 to 56 d after dose administration.  183 
 184 
Calculation of β-carotene relative bioefficacy using the isotope reference method.  Relative 185 
bioefficacy was calculated for the same data using the IRM as applied by Tang et al. (14) and 186 
Green et al. (6) as shown in Equation 2: 187 
 188 
                       IRM relative bioefficacy (%) = (AUCp for labeled β-carotene-derived retinol / 189 
                                AUCp for labeled retinyl acetate-derived retinol) × 100    (2) 190 
 191 
The trapezoid rule was applied to FDp data using GraphPad Prism v. 7.0 for Windows (GraphPad 192 
Software Inc., La Jolla, CA) to determine AUCp from time zero to the end of the experiment (56 d) 193 
or to earlier times.   194 
 195 
Comparison of calculated values for relative bioefficacy to known values.  β-Carotene 196 
bioefficacies calculated for each individual using the plasma RIR (Equation 1) and the IRM 197 
(Equation 2) were compared to the known (assigned) values for total, absorptive, and post-198 
absorptive (both early and late) bioefficacy in order to evaluate the accuracy of the two 199 
techniques. 200 
 201 
Application of the plasma retinol isotope ratio and the isotope reference method to previously-202 
published kinetic data.  We expanded the application of the plasma RIR (Equation 1) and IRM 203 
(Equation 2) to estimate β-carotene relative bioefficacy for the group of healthy young adults 204 
(n=30) that had been previously studied by Green et al. (6).  In that paper, relative bioefficacies 205 
were calculated using the model-based AUCp method in WinSAAM [i.e., (plasma residence time 206 
for β-carotene-derived retinol divided by plasma residence time for retinyl acetate-derived retinol) 207 
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x 100].  These values were compared in (6) to estimates calculated using the IRM at 14 d; results 208 
for the plasma RIR at d 2 were also mentioned in (6).  For the current analysis, relative 209 
bioefficacy was calculated using Equations 1 and 2 at 1, 2, 7, and 14 d.   210 
 211 
Statistical analysis.  Figures were prepared and linear regression analysis was done using 212 
GraphPad Prism v. 7.0 for Windows.  To identify time-dependent changes in bioefficacy 213 
calculated using the RIR and IRM for subjects from (6), we used repeated measures ANOVA 214 
(JMP® Pro v. 12.1.0; SAS Institute Inc., Cary, NC) and to assess within-subject differences in 215 
predictions, we used matched pairs analysis (JMP® Pro v. 12.1.0).  P < 0.05 was considered 216 
significant.   217 
 218 
Results 219 
Confirmation of assigned (known) values for β-carotene bioefficacy.  We used model simulations 220 
as described in Supplemental Methods 1 to confirm that our physiologically-based compartmental 221 
model (Figure 1B) accurately predicted the assigned values for the various components of 222 
bioefficacy (total, absorptive, and early and late post-absorptive) for each individual.  As shown in 223 
Figure 2 for subject 5, the simulation correctly predicted the assigned values for total (actual, not 224 
relative) bioefficacy (18.75%), absorptive bioefficacy (15%), and post-absorptive bioefficacy 225 
(3.75%), as well as the components of post-absorptive (early at 1.69% and late at 2.06%).  For 226 
this subject, values for all components plateaued by 5 d and were time invariant after that.  Model 227 
simulations also precisely predicted assigned (known) values for bioefficacy, including all forms of 228 
bioconversion, for the other nine subjects (data not shown). 229 
 230 
Plasma isotope response data/curves for the retinol reference dose and for β-carotene-derived 231 
retinol.  Using the model shown in Figure 1A and the kinetic parameters from Cifelli et al. (15) and 232 
Green et al. (6) that are presented in Supplemental Table 1, we simulated tracer data for plasma 233 
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retinol derived from the retinyl acetate reference dose versus time.  As shown in Figures 3A and 234 
B (solid lines) for subjects 2 and 8, respectively, plasma retinol tracer peaked ~13 h after dosing 235 
and then gradually fell as retinol was distributed to tissues.  The bend in the curves at ~7 d 236 
indicates recycling of tracer back to plasma.  By 10 d post-dosing, the curves entered a terminal 237 
slope, equivalent to the apparent system fractional catabolic rate (~3%/d for these two subjects).  238 
Similar patterns were observed for the retinyl acetate-derived retinol curves for the other subjects 239 
(data not shown). 240 
Also presented in Figures 3A and B are the simulated plasma tracer response data for β-241 
carotene-derived retinol (dashed lines) when relative bioefficacy was fixed at 14% (10% 242 
absorptive and 4% post-absorptive; subject 2) or at 40% (30% absorptive and 10% post-243 
absorptive; subject 8).  Note that, at the higher (versus lower) level of total β-carotene bioefficacy, 244 
the curve for β-carotene-derived retinol is closer to the one for retinol from the reference dose.  245 
For all subjects (data not shown), before any late post-absorptive conversion occurred, curves for 246 
β-carotene-derived retinol were similar to those for retinyl acetate-derived retinol (i.e., the two 247 
curves appeared to be parallel, as illustrated in Figures 3A and B).  At the time set for late post-248 
absorptive conversion (delay component 22; Figure 1B), which was varied from 2 to 5 d across 249 
subjects (Supplemental Table 1), there was an increased influx of tracer into plasma as newly-250 
formed labeled retinol was secreted into compartment 15.  At the higher levels of post-absorptive 251 
conversion (7 to 20%), the increased input was evident as a discernible hump in the curves for β-252 
carotene-derived retinol (as illustrated by the data in Figure 3B), whereas at the lower levels of 253 
post-absorptive conversion (3 to 5%), this influx caused only subtle changes in the curves (as in 254 
Figure 3A).  Plasma retinol tracer stabilized after late post-absorptive conversion and the curves 255 
entered a terminal slope by ~10 d, becoming parallel to the curve for retinyl acetate-derived 256 
retinol.   257 
Next, to examine the two components of bioefficacy separately, we used model-based 258 
compartmental analysis to simulate the expected plasma isotope response curves for β-carotene-259 
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derived retinol formed from absorptive versus post-absorptive conversion.  Figure 4 shows these 260 
simulations, along with the curve for retinol derived from the reference dose, for subject 5; see 261 
also Supplemental WinSAAM Deck.  As was the case for all subjects (data not shown), the 262 
curve for absorptive bioconversion (dash-dot line in Figure 4) peaked at ~13 h, similar to that for 263 
the retinyl acetate-derived retinol (solid line); curves were parallel from this point on.  The curve 264 
for post-absorptive conversion (dotted line) showed two distinct peaks.  The first peak occurred 265 
~13 h after dosing, similar to that for the absorptive phase, representing early post-absorptive 266 
conversion, whereas the second peak occurred after late post-absorptive conversion (2.5 d).  Our 267 
model simulation predicts that a portion of the retinol formed during early post-absorptive 268 
conversion enters plasma with the same time course as intestinally-produced retinol; see 269 
Discussion.  When there is extensive late post-absorptive conversion, there is a hump in the 270 
composite curve for β-carotene-derived retinol (absorptive plus post-absorptive; dashed line).  271 
After ~10 d, the curves for β-carotene-derived retinol parallel that for the retinyl acetate-derived 272 
retinol for the duration of the experiment (56 d). 273 
 274 
β-Carotene relative bioefficacy calculated by the RIR and IRM.  Relative bioefficacies predicted 275 
by the plasma RIR (Equation 1) and the IRM (Equation 2) were compared to known (assigned) 276 
values for total, absorptive, and post-absorptive relative bioefficacy for the ten subjects (Table 1).  277 
For all subjects, the plasma RIR accurately predicted known values for total relative bioefficacy 278 
from 14 d to the end of the experiment (56 d); specifically, the RIR at either 14 or 56 d predicted a 279 
mean of 101% of the known values (range, 100 to 103%).  Bioefficacy estimates calculated by 280 
the IRM predicted a mean of 92% (range, 74 to 99%) and 95% (range, 84 to 100%) of total 281 
bioefficacy at 14 and 56 d, respectively.  For 8 of the 10 subjects, the IRM predictions were very 282 
close to the known values (96 and 98% of the total at 14 and 56 d, respectively)    283 
We then compared the equations’ predictions on d 1 to known values for absorptive 284 
bioefficacy, as has been done in earlier applications of the IRM when the prediction on 1 d has 285 
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been said to indicate intestinal bioconversion (14, 22).  The d 1 plasma RIR overestimated the 286 
assigned values for absorptive bioconversion by a mean of 17% and the IRM overestimated them 287 
by 26% (Table 1), suggesting that the d 1 predictions included more than absorptive conversion.  288 
As shown in Figure 4 inset, at 1 d, the composite curve for β-carotene-derived retinol (dashed 289 
line) is higher than the curve for retinol derived from intestinal conversion (dash-dot line).  This 290 
difference is attributable to a contribution from early post-absorptive conversion (see Discussion).  291 
Note that, when the plasma RIR and IRM were calculated using the appropriate simulated data 292 
for retinol derived from intestinal β-carotene conversion and the retinyl acetate reference dose, 293 
both methods predicted known values for absorptive bioefficacy at all times from 1 d on (data not 294 
shown).  When known values for absorptive and early post-absorptive bioefficacy were added 295 
together using data in Table 1, the RIR at 1 d predicted a mean of 96% of the sum (range, 85 to 296 
103%); the linear regression equation was y = 0.95x + 1.8 (R2 = 0.99), where y is the known 297 
value for absorptive plus early post-absorptive bioefficacy and x is the RIR on d 1.  This indicates 298 
that, on average, ~4% of the retinol produced by early post-absorptive conversion appeared in 299 
plasma after d 1 and is included in the prediction of bioefficacy at 14 d.  For the IRM, calculations 300 
on d 1 predicted 100% (range, 79 to 120%) of the sum of the absorptive plus early post-301 
absorptive bioefficacy.  Thus, in contrast to previous assumptions that d 1 predictions by the IRM 302 
represent absorptive bioconversion (14), our model predicts that d 1 data include not only the 303 
absorptive but also some of the early post-absorptive conversion of β-carotene to retinol. 304 
To illustrate the changes in relative bioefficacy calculated by the RIR and IRM over time, 305 
we present in Figure 5 results for subject 7 who was assigned 35% total relative bioefficacy, 306 
partitioned into 28% absorptive and 7% post-absorptive (2.1% early and 4.9% late).  For this 307 
subject, the plasma RIR at 1 d predicted a relative bioefficacy of 30%, close to the known value 308 
for absorptive plus early post-absorptive bioefficacy (30.1%).  After late post-absorptive 309 
conversion occurred (4.5 d for subject 7) and newly converted retinol derived from β-carotene 310 
entered plasma, the RIR was higher (i.e., the numerator in Equation 1 increased), peaking at 6.5 311 
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d at 48% (138% of the total).  The value then fell and stabilized by 14 d at 35.5%, near the known 312 
value for total relative bioefficacy (35%).  For all subjects, the peak in the RIR occurred between 4 313 
and 7 d post-dosing; by 14 d, the RIR stabilized near the known value for total relative bioefficacy.  314 
Similar trends versus time were observed for the other subjects (data not shown).  These results 315 
show that the RIR is highly responsive to late post-absorptive conversion and needs time to 316 
stabilize; for these subjects, when late conversion occurred between 2 and 5 d, stabilization in the 317 
ratio was evident by 14 d.   318 
In the case of the IRM, predictions for subject 7 (Figure 5) gradually increased following 319 
late post-absorptive conversion, averaging 92 and 95% of the total bioefficacy at 14 and 56 d, 320 
respectively.  Similar trends were observed for the other subjects (data not shown).  Overall, the 321 
IRM predictions at 14 or 56 d were close to the assigned values for total relative bioefficacy, 322 
except when there was substantial (late) post-absorptive conversion.  Specifically, at the two 323 
highest levels of late post-absorptive bioconversion (subjects 6 and 10; Table 1), the IRM 324 
underestimated total relative bioefficacy by ~25% at 14 d and ~15% at 56 d.   325 
 326 
Comparison of predictions of the plasma RIR and the IRM when applied to previously-published 327 
retinol kinetic and bioefficacy data.  We applied Equations 1 (RIR) and 2 (IRM) to previously-328 
published data (6) for 30 adults for whom bioefficacy had been estimated using WinSAAM.  Mean 329 
values for relative bioefficacy predicted by the RIR and IRM are plotted over time in Figure 6.  330 
Predictions of the two equations were similar at 1 and 2 d (~12%).  For the plasma RIR, 331 
predictions were significantly higher on d 7 and d 14 (~15%) compared to d 1 and 2, indicating 332 
that some post-absorptive conversion of β-carotene to retinol (~3%) occurred between 2 and 7 d 333 
in some of these subjects, even though plasma isotope response curves for subjects in (6) 334 
suggested little to no post-absorptive conversion.  Based on our theoretical work, we hypothesize 335 
that predictions of relative bioefficacy by the RIR at 1 and 2 d include all of the absorptive and 336 
most of the early post-absorptive bioconversion, and estimates at 7 and 14 d include the late 337 
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post-absorptive conversion as well.  For the IRM, predictions were higher on 7 d versus d 1 and 338 
2, and higher still on 14 d (~13%), also suggesting some post-absorptive bioconversion (~1%).  339 
For individual comparisons, the RIR on d 14 predicted significantly higher values for relative 340 
bioefficacy compared to the IRM, by a mean difference of 2.3% bioefficacy (P < 0.0001).  Relative 341 
bioefficacy predicted by the RIR on d 14 ranged from 4.6 to 37.1% over all subjects, whereas for 342 
the IRM, 14 d predictions ranged from 4.5 to 30.7%.  The maximum difference in relative 343 
bioefficacy values at 14 d versus 1 d was 7.7% for the RIR and 5.1% for the IRM.  These results 344 
suggest that the RIR is more responsive than the IRM to (late) post-absorptive bioconversion, 345 
even when little occurs.  Based on our theoretical analysis, we suggest that the RIR likely 346 
provides a more accurate estimate of β-carotene relative bioefficacy using data from a single 347 
blood sample obtained at 14 d or later.   348 
 349 
Discussion  350 
In this paper, we show (Table 1) that β-carotene relative bioefficacy is accurately estimated 351 
based on the ratio of two retinol isotopes in a single plasma sample (Equation 1) obtained at 14 352 
or more days after co-ingestion of labeled β-carotene and a labeled retinyl acetate reference 353 
dose.  Such an approach had been previously suggested by Hickenbottom et al. (9) and Green et 354 
al. (6) but had not been evaluated or used.  The single sample approach will make it more 355 
feasible to measure β-carotene relative bioefficacy in field settings, where it can be difficult to 356 
obtain multiple samples over time, as is done when using the isotope reference method (Equation 357 
2) to estimate relative bioefficacy (13).  In addition, the single sample method will facilitate 358 
measuring bioefficacy in children, in whom repeated sampling is difficult.  It is worth noting that 359 
investigators could also assess vitamin A status by collecting an additional blood sample at 4 or 5 360 
d and applying an appropriate retinol isotope dilution equation to the retinyl acetate-derived retinol 361 
data to predict individual vitamin A total body stores (23).  362 
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To our knowledge, this study is the first to evaluate the accuracy of methods for estimating 363 
β-carotene relative bioefficacy.  We used model-based compartmental analysis (11) and model 364 
simulations to verify predictions of known (assigned) values for bioefficacy (Figure 2) and then 365 
applied Equations 1 and 2 to calculate relative bioefficacy using simulated plasma retinol tracer 366 
response data.  This approach is similar to the one we recently used to test the accuracy of an 367 
equation for estimating vitamin A total body stores at isotopic equilibrium (24).  Here, in addition 368 
to demonstrating that the plasma RIR accurately predicts β-carotene relative bioefficacy at 14 d 369 
or later after dosing, we also showed that the IRM accurately predicts relative bioefficacy for 370 
some subjects (specifically, those with low levels of late post-absorptive bioconversion).  It would 371 
be interesting for other investigators to now apply the RIR retrospectively to their previously-372 
collected data from IRM studies to compare results for the two methods.   373 
It should be emphasized that both the plasma RIR and IRM estimate bioefficacy relative to 374 
the absorption efficiency of the co-administered retinyl acetate reference dose.  As methods are 375 
developed for measuring vitamin A absorption efficiency, it will be possible to correct estimates of 376 
β-carotene relative bioefficacy by including the actual value for absorption efficiency of the 377 
reference dose (bioefficacy = relative bioefficacy × reference dose absorption efficiency). 378 
In addition to providing a way to evaluate the accuracy of methods for estimating β-379 
carotene relative bioefficacy, compartmental modeling also led to insights into the time course 380 
and likely pathways for conversion of absorbed β-carotene to retinol.  For provitamin A, previous 381 
work (14, 17, 22, 25) has suggested that some of the absorbed carotenoid is converted to retinol 382 
in the intestine and another portion is converted later (post-absorptive bioconversion) in tissues 383 
such as liver and adipose tissue.  Starting with these assumptions, the model (Figure 1B) 384 
developed to generate plasma isotope response data for retinol derived from β-carotene included 385 
a site (delay component 13) for partitioning absorbed β-carotene destined for intestinal 386 
conversion (compartment 14) or for post-absorptive conversion (compartment 21).  We 387 
hypothesize that β-carotene in chylomicrons taken up by the liver or extrahepatic tissues could be 388 
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converted to retinol (compartment 24) soon after uptake, representing the early post-absorptive 389 
phase.  Alternatively, β-carotene could be transferred from compartment 21 to delay component 390 
22 and compartment 23, representing the late post-absorptive conversion pathway.  The late 391 
post-absorptive route might involve β-carotene incorporation into very low density lipoproteins in 392 
the liver, with release of those lipoproteins into the circulation and subsequent metabolism to low- 393 
and high density lipoproteins (delay component 22), followed by uptake of plasma lipoprotein β-394 
carotene by tissues in which post-absorptive bioconversion can occur.  Alternatively, the late 395 
post-absorptive route might involve uptake of chylomicron β-carotene into (for example) adipose 396 
tissue and then partitioning into lipid droplets with subsequent conversion to retinol (compartment 397 
24).  As shown in Figure 1B, this retinol can either be secreted into plasma compartment 15 398 
bound to retinol-binding protein or it can be esterified for storage in compartment 16.   399 
Plasma isotope response curves like the one for β-carotene-derived retinol in Figure 3 400 
reflect the composite impact on retinol kinetics of all β-carotene bioconversion processes that 401 
result in the appearance of labeled retinol in plasma; methods like the RIR and IRM estimate 402 
relative bioefficacy using plasma retinol tracer data.  Thus, if some absorbed β-carotene is 403 
converted locally in tissues to biologically active forms of vitamin A (26) or to apocarotenoids (27), 404 
those compounds never reach plasma as retinol and so these quantitatively minor pathways do 405 
not contribute to bioefficacy as currently defined (2).  406 
As illustrated in Figure 4, one can use model simulations to look at the likely time course 407 
of the individual components of bioefficacy.  This analysis revealed two distinct peaks in the curve 408 
for retinol derived from post-absorptive conversion:  the first, corresponding to early post-409 
absorptive conversion, occurs at the same time (~13 h after dose ingestion) as the peak in the 410 
curve for retinol generated by absorptive bioconversion; the second peak (at 2.5 d) corresponds 411 
to the late post-absorptive process.  Depending on the extent of late post-absorptive conversion, 412 
there may be a discernible “hump” in the composite curve for β-carotene-derived retinol 413 
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(absorptive plus post-absorptive).  This is evident in Figure 3B and can be seen in the results of 414 
other investigators (14, 17, 28).  415 
 Our current results suggest that retinol formed from early post-absorptive conversion 416 
enters plasma with the same time course as intestinally-produced retinol.  Thus, based on our 417 
model, predictions of the plasma RIR at 1 d include retinol derived from absorptive conversion 418 
and some (probably most) of the early post-absorptive conversion; the early post-absorptive 419 
component might include some conversion of the labeled β-carotene dose that occurs in the 420 
intestine following subsequent meals.  In earlier applications of the isotope reference method (14, 421 
22), d 1 results have been interpreted to represent intestinal bioconversion.  Similar to results by 422 
Tang et al. (14) which indicated that 81% of the total β-carotene conversion to vitamin A had 423 
occurred by 1 d, our results indicate that for the RIR, 81% of the total relative bioefficacy was 424 
predicted at 1 d (86% for the IRM).  By collecting a blood sample at 1 d as well as 14 d, 425 
researchers could use the RIR to estimate the contribution of absorptive- and early post-426 
absorptive conversion to total relative bioefficacy.   427 
Our data indicate that, after late post-absorptive conversion, the RIR transiently 428 
overestimates relative bioefficacy before stabilizing at the correct value for “total” bioefficacy by 429 
14 d.  Time for ratio stabilization is also required for the plasma dual isotope ratio method used to 430 
determine cholesterol absorption (7) and vitamin A absorption (8).  It is interesting to note that, if 431 
RIR predictions on d 14 for a given individual are substantially higher than those on d 1, this 432 
indicates that late post-absorptive bioconversion is an important contributor to total bioefficacy in 433 
that subject. 434 
In conclusion, compared to graphical methods (e.g., the isotope reference method), the 435 
plasma retinol isotope ratio provides a simpler and more accurate method for estimating 436 
carotenoid relative bioefficacy following co-administration of isotope-labeled doses of β-carotene 437 
and retinyl acetate (reference dose).  The plasma retinol isotope ratio method should be valid for 438 
use in both children and adults, and it can be used for test solutions (e.g., isotopes administered 439 
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in oil) or for intrinsically-labeled carotenoid in foods.  The plasma RIR predicts β-carotene relative 440 
bioefficacy based on analysis of one blood sample collected 14 d or more after dosing.     441 
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TABLE 1  Assigned (known) and predicted values for β-carotene relative bioefficacy (%) for ten subjects1  
Subject 1 2 3 4 5 6 7 8 9 10 
Assigned values           
    Total 10 14 18 21 25 30 35 40 45 50 
    Absorptive 7 10 9 16 20 15 28 30 40 30 
    Post-absorptive 3 4 9 5 5 15 7 10 5 20 
            Early 2.4 3 6.75 4.25 2.25 5.25 2.1 2 2.5 2 
            Late 0.6 1 2.25 0.75 2.75 9.75 4.9 8 2.5 18 
Values predicted by RIR 
1 d 8.1 12.9 13.6 19.6 23.0 17.2 29.8 32.7 41.8 31.5 
2 d 8.3 11.0 12.0 20.5 22.0 17.1 29.7 32.7 40.8 31.0 
4 d 11.2 15.6 23.2 20.6 32.1 40.8 29.3 34.4 41.1 31.0 
7 d 10.0 14.2 18.1 22.5 27.3 31.5 47.8 69.2 49.2 62.9 
14 d 10.0 14.0 18.1 21.1 25.2 30.4 35.5 40.9 45.1 51.3 
21 d 10.0 14.0 18.1 21.1 25.2 30.4 35.4 40.8 45.1 51.4 
28 d 10.0 14.0 18.1 21.1 25.2 30.4 35.4 40.8 45.1 51.4 
56 d 10.0 14.0 18.1 21.1 25.2 30.4 35.4 40.8 45.1 51.4 
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1 Values are percent β-carotene relative bioefficacy for 10 subjects selected from previously published studies (6, 15).  The top 
section shows values for relative bioefficacy [total, absorptive, and post-absorptive (early and late)] that were assigned to each 
subject as described in Methods.  The middle section shows predictions of the plasma retinol isotope ratio [RIR; Equation 1 (see 
Methods)] versus time after co-ingestion of an oral dose of stable isotope-labeled β-carotene and a retinyl acetate reference dose; 
the bottom section shows predictions of the isotope reference method [IRM; Equation 2 (see Methods)] versus time after dosing. 
Values predicted by IRM 
1 d 10.1 15.6 18.3 20.2 23.3 16.0 27.2 30.1 42.7 29.9 
2 d 9.2 13.8 15.6 20.0 23.0 16.6 28.7 31.6 42.1 30.6 
4 d 9.2 13.6 15.2 20.1 23.1 17.4 29.0 31.9 41.7 30.7 
7 d 9.4 13.9 16.3 20.7 24.5 20.0 30.5 36.8 42.5 36.3 
14 d 9.6 13.9 16.8 20.8 24.7 22.1 32.2 38.7 42.9 38.4 
21 d 9.7 13.9 17.0 20.8 24.8 23.4 32.6 38.9 43.1 39.5 
28 d 9.8 13.9 17.1 20.9 24.8 24.2 32.8 39.1 43.3 40.4 
56 d 9.8 14.0 17.3 20.9 24.9 25.8 33.3 39.4 43.7 42.2 
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Figure Legends  
1. Proposed compartmental models for retinol kinetics in humans following co-ingestion of 
labeled β-carotene and labeled retinyl acetate.  Circles represent compartments, rectangles 
correspond to delay components, interconnectivities between compartments [L(I,J)s] are 
fractional transfer coefficients or the fraction of retinol or β-carotene molar retinol activity 
equivalents transferred to compartment I from compartment J each day, and delay times 
[DT(I)] correspond to the time spent in delay component I.  The asterisks represent the site 
of input of the orally administered tracers; U(1) and U(11) represent dietary vitamin A and β-
carotene input, respectively; and the triangles represent the site of sampling (plasma).  
Panel A shows the six-compartment model adapted from (6) that describes the metabolism 
of retinyl acetate-derived labeled retinol.  Compartments 1 to 4 represent the processing of 
dietary preformed vitamin A; fractional absorption of retinyl acetate was set at 0.75.  Diet-
derived vitamin A is taken up by hepatocytes (compartment 4), primarily as retinyl esters, 
and then retinol is secreted into plasma compartment 5 bound to retinol-binding protein; 
retinol in the plasma pool exchanges with vitamin A in the extravascular storage pool 
(compartment 6), which is the site of irreversible loss from the system.  Panel B shows the 
ten-compartment model developed to describe the metabolism of β-carotene-derived retinol 
during absorptive (intestinal) conversion (unshaded components) as well as early and late 
post-absorptive (extra-intestinal) conversion (shaded components).  Components 11 to 13 
represent gastrointestinal transit and absorption of β-carotene; in compartment 11, absorbed 
β-carotene is partitioned into the fraction eventually converted to retinol (that which is 
transferred to compartment 12) versus that which is not converted [(L0,11)], and in delay 
component 13, bioefficacy is partitioned into absorptive and post-absorptive components.  
For the absorptive pathway, retinol (primarily as retinyl esters) derived from absorbed β-
carotene is transferred to compartment 14 and processed as described above in 
compartments 15 and 16.  For the post-absorptive pathway, absorbed β-carotene is 
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transferred from component 13 to compartment 21, representing uptake by hepatic and 
extrahepatic tissues.  For the early post-absorptive pathway (solid-line arrow), some of this 
β-carotene in compartment 21 is converted in situ to retinol (compartment 24).  For the late 
post-absorptive pathway (dashed-line arrows), the β-carotene passes from compartment 21 
through component 22 and compartment 23 before entering compartment 24.  Retinol in 
compartment 24 can either be secreted directly into plasma (compartment 15) or esterified 
for storage (compartment 16).  βC, β-carotene; ROH, retinol; RE, retinyl esters.   
2. Model simulations for fraction of the β-carotene dose in various compartments versus time 
for subject 5.  Shown are fraction of dose (as molar retinol activity equivalents) in model 
compartments (Figure 1B) that were designated as sinks (see Supplemental Methods 1) for 
total (compartment 12), absorptive (compartment 14), and post-absorptive bioefficacy 
(compartment 21), as well as for the early (compartment 24 with no input from compartment 
23) and late post-absorptive components (compartment 23).  Assigned values for bioefficacy 
(%) are indicated at each curve’s plateau.   
3. Model-predicted plasma retinol response curves versus time after co-ingestion of labeled β-
carotene and labeled retinyl acetate for two subjects.  Shown are simulated data for fraction 
of dose in molar retinol activity equivalents over time for labeled retinol derived from the 
retinyl acetate reference dose and from the β-carotene dose.  Panel A shows simulations for 
subject 2 (Table 1) who was assigned values of 14% total relative bioefficacy (10% 
absorptive plus 4% post-absorptive bioconversion) with late post-absorptive conversion set 
at 2 d; panel B shows the corresponding simulations for subject 8 (40% total, of which 30% 
was absorptive and 10% post-absorptive); late post-absorptive conversion was set at 3.5 d. 
4. Model-predicted plasma retinol response curves versus time after co-ingestion of labeled β-
carotene and labeled retinyl acetate for subject 5.  Shown are simulated values for fraction 
of dose in molar retinol activity equivalents over time (shown on a semi-log scale) for labeled 
retinol derived from the retinyl acetate reference dose and for β-carotene-derived retinol, as 
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well as retinol formed from absorptive and post-absorptive conversion of β-carotene.  
Subject 5 (Table 1) was assigned 25% total relative bioefficacy (20% absorptive plus 5% 
post-absorptive, with 2.25% early post-absorptive and 2.75% late post-absorptive).  The 
inset shows these simulations for β-carotene-derived retinol on an expanded (linear) scale 
between 3 h and 10 d. 
5. β-Carotene relative bioefficacy calculated by two methods.  The plasma retinol isotope ratio 
(RIR; see Methods, Equation 1) and the isotope reference method (IRM; Equation 2) were 
used to calculate β-carotene relative bioefficacy over time for subject 7 (Table 1) who was 
assigned a value of 35% total relative bioefficacy (28% absorptive plus 7% post-absorptive); 
late post-absorptive conversion was set at 4.5 d post-dosing. 
6. β-Carotene relative bioefficacy predicted by two methods for previously-studied adults (6).  
Values are means ± SEM (n=30) for relative bioefficacy calculated at four times after co-
ingestion of labeled β-carotene and a labeled retinyl acetate reference dose; values were 
calculated using the plasma retinol isotope ratio (RIR; see Methods, Equation 1) and the 
isotope reference method (IRM; Equation 2).  Means within each method that have different 
letters are significantly different (P < 0.05) using repeated measures ANOVA. 
